Holen Sie sich die Stockscreener-App
2.505
2.91%
-0.075
Handel nachbörslich:
2.64
0.135
+5.39%
Schlusskurs vom Vortag:
$2.58
Offen:
$2.58
24-Stunden-Volumen:
141.77K
Relative Volume:
0.34
Marktkapitalisierung:
$89.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-27.39%
1M Leistung:
-26.11%
6M Leistung:
-77.93%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.50
$2.625
1-Wochen-Bereich:
$2.50
$3.56
52-Wochen-Spanne:
$1.0779
$55.00
Fibrobiologics Inc Stock (FBLG) Company Profile
Firmenname
Fibrobiologics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie FBLG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| FBLG | 2.505 | 89.40M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Fibrobiologics Inc Aktie (FBLG) Neueste Nachrichten
HC Wainwright Expects Stronger Earnings for FibroBiologics - MarketBeat
Fibrobiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction in Cell-Based Therapeutics - Marketscreener.com
FibroBiologics files patent for reducing cell therapy risks - Investing.com
FibroBiologics seeks patent for clot-prevention method - Investing.com
FibroBiologics Files Patent Application Covering Reduction - GlobeNewswire
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with ... - The Bakersfield Californian
FibroBiologics Files Patent for Breakthrough Cell Therapy Blood Clotting Prevention | FBLG Stock News - StockTitan
Is FibroBiologics (NASDAQ:FBLG) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
FibroBiologics' (FBLG) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Reports Wider Q3 Loss, Advances Clinical Pipeline Amid R&D Push | FBLG Stock News - StockTitan
FibroBiologics Inc. (FBLG) Quarterly 10-Q Report - Quartzy
FBLGFibroBiologics, Inc. Latest Stock News & Market Updates - StockTitan
HC Wainwright Begins Coverage on FibroBiologics (NASDAQ:FBLG) - Defense World
HC Wainwright Forecasts FibroBiologics Q3 Earnings - MarketBeat
H.C. Wainwright sets stock target on FibroBiologics shares, cites portfolio By Investing.com - Investing.com Australia
FibroBiologics (NASDAQ:FBLG) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
FibroBiologics names interim CFO as Mark Andersen steps down By Investing.com - Investing.com Australia
FibroBiologics CFO Andersen Resigns - MarketWatch
FibroBiologics names interim CFO as Mark Andersen steps down - Investing.com India
FibroBiologics reports breakthrough in artificial thymus research - Investing.com
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology - GlobeNewswire
FibroBiologics, Inc. Announces Updates for Novel Artificial Thymus Organoid Technology - Marketscreener.com
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024 - GlobeNewswire
FibroBiologics and Charles River link for chronic disease therapies manufacture - Yahoo News
FibroBiologics, Charles River Partner To Manufacture Cell-Based Therapies - Contract Pharma
FibroBiologics partners with Charles River for DFU trial production - Investing.com
FibroBiologics and Charles River Announce Collaboration to - GlobeNewswire
FibroBiologics partners with Charles River for DFU trial production By Investing.com - Investing.com UK
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based ... - Post Register
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases - ForexTV.com
FibroBiologics Shares Rise After European Patent for Fibroblast Cancer Treatment - MarketWatch
FibroBiologics secures patent for cancer treatment method - Investing.com
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office - GlobeNewswire
Short Interest in FibroBiologics, Inc. (NASDAQ:FBLG) Increases By 21.6% - MarketBeat
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit - The Manila Times
FBLG Stock Earnings: FibroBiologics, Inc. – Common Stock Reported Results for Q1 2024 - MSN
FibroBiologics, Inc. (NASDAQ:FBLG) Short Interest Update - MarketBeat
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa - GlobeNewswire
Take off with FibroBiologics Inc (FBLG): Get ready for trading - SETE News
FibroBiologics (NASDAQ:FBLG) Now Covered by Analysts at Maxim Group - MarketBeat
Maxim Group Initiates Coverage of FibroBiologics (FBLG) with Buy Recommendation - MSN
Market Insights: FibroBiologics Inc (FBLG)’s Notable Gain of 4.43, Closing at 3.30 - The Dwinnex
Falcon’s Beyond Global, Inc. (NASDAQ:FBYDW) Short Interest Update - Defense World
FibroBiologics engages Southern Star Research as CRO in Australia - TipRanks
FibroBiologics Engages Southern Star Research as CRO in Australia - GlobeNewswire
Five9, Inc. (NASDAQ:FIVN) Shares Acquired by Edgestream Partners L.P. - Defense World
FibroGen Inc (FGEN) can make a big difference with a little luck - SETE News
FibroGen Inc (FGEN) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Brown Brothers Harriman & Co. Has $104,000 Holdings in Fidus Investment Co. (NASDAQ:FDUS) - Defense World
Finanzdaten der Fibrobiologics Inc-Aktie (FBLG)
Es liegen keine Finanzdaten für Fibrobiologics Inc (FBLG) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Fibrobiologics Inc-Aktie (FBLG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Khoja Hamid | Chief Scientific Officer |
Aug 12 '24 |
Buy |
1.90 |
10,000 |
19,000 |
11,250 |
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):